A5070868323- CAR-T cell therapy research
- HER2/EGFR in Cancer Research
- Immune Cell Function and Interaction
- Breast Cancer Treatment Studies
- Immunotherapy and Immune Responses
- Advanced Breast Cancer Therapies
- T-cell and B-cell Immunology
- Virus-based gene therapy research
- Monoclonal and Polyclonal Antibodies Research
- Human-Animal Interaction Studies
- Toxin Mechanisms and Immunotoxins
- Cancer Treatment and Pharmacology
- Multiple and Secondary Primary Cancers
- Viral Infectious Diseases and Gene Expression in Insects
- Gut microbiota and health
- Cancer Research and Treatments
- Hemophilia Treatment and Research
- Peptidase Inhibition and Analysis
- Reproductive System and Pregnancy
- Cancer Immunotherapy and Biomarkers
- Congenital heart defects research
- Platelet Disorders and Treatments
- Ethics in Clinical Research
- Cardiovascular Conditions and Treatments
- Chronic Lymphocytic Leukemia Research
Texas A&M University
2022-2025
Georgia College & State University
2023
University of Georgia
2023
Nkarta Therapeutics (United States)
2020
Aichi Cancer Center
2019
Centro de Investigación Biomédica en Red de Cáncer
2019
Sana Klinikum Offenbach
2019
GEICAM – Spanish Breast Cancer Group
2019
Analysis Group (United States)
2016
Tennessee Oncology
2016
Abstract CD4+CD25+ regulatory T cells (Tregs) mediate peripheral T-cell homeostasis and contribute to self-tolerance. Their homeostatic pathologic trafficking is poorly understood. Under conditions, we show a relatively high prevalence of functional Tregs in human bone marrow. Bone marrow strongly expresses stromal-derived factor (CXCL12), the ligand for CXCR4. Human traffic are retained through CXCR4/CXCL12 signals as shown chimeric nonobese diabetic/severe combined immunodeficient mice....
Oncolytic adenoviruses, which selectively replicate in and subsequently kill cancer cells, have emerged as a promising approach for treatment of tumors resistant to other modalities. Although preclinical results been exciting, single-agent clinical efficacy has less impressive heretofore. The immunogenicity consequent premature abrogation replication, may partial reason. Improving the oncolytic potency agents hampered by inability study host–vector interactions immune-competent systems,...
Purpose The antibody-drug conjugate trastuzumab emtansine (T-DM1) has improved outcomes in patients with human epidermal growth factor receptor 2 (HER2)–positive metastatic breast cancer (MBC), as demonstrated phase III studies. Few data approximating its use routine clinical practice are available. Methods T-DM1 Patient Access Study was an expanded-access, multicenter study of US pretreated HER2–positive locally advanced or MBC. primary endpoint safety. secondary investigator-assessed...
Geroscience studies of low-dose rapamycin in laboratory species have identified numerous benefits, including reversing age-related cardiac dysfunction. Cardiovascular benefits been observed dogs with 10 weeks treatment, raising questions about possible and adverse effects long-term use rapamycin. The objectives this study were to assess the impact 6 months on echocardiographic indices function healthy document occurrence events.Seventeen client-owned aged 6-10 years, weighing 18-36 kg,...
Extended abstract of a paper presented at Microscopy and Microanalysis 2011 in Nashville, Tennessee, USA, August 7–August 11, 2011.
Adenoviral (Ad) vector-mediated strategies for cancer gene therapy mandate a vector that is capable of efficient expression the therapeutic specifically within target tumor cells. In one approach to development cell-specific vectors, Ad vectors have been targeted at level transduction achieve selective delivery gene. an alternative derivation transcription by placing under control transcriptional regulatory sequences are activated in cells, but not normal and therefore selectively cell. this...
Objective: This retrospective study compared the real-world incidence and costs of systemic treatment-related adverse events (AEs) in patients with metastatic breast cancer a Medicaid population.Methods: Insurance claims data for adult women who received biologic or chemotherapy (± hormonal therapy) between 2006–2013 were extracted from Truven Health MarketScan® Multi-State database. Incidence AEs (per 100 person years) average monthly AE-related healthcare (per-patient-per-month) during...
Abstract OBJECTIVE The researchers and clinicians within the Dog Aging Project (DAP), a longitudinal cohort study of aging in companion dogs, created validated novel survey instrument titled End Life Survey (EOLS) to gather owner-reported mortality data about dogs. SAMPLE Bereaved dog owners who participated refinement, face validity assessment, or reliability assessment EOLS (n = 42) and/or completed entire between January 20 March 24, 2021 (646). PROCEDURES was modified by veterinary...
The present study was conducted to determine the effects of bone sialoprotein (BSP) in promoting vascular invasion tumor cells metastasis. We used a Matrigel system and MDA-231 human breast cancer transfected with BSP cDNA (MDA-231/BSP). Quantative analysis indicated an average 1.7-fold increase cell numbers that migrated through endothelial MDA-231/BSP compared empty vector-transfected (MDA-231/EV). In vivo assay, were incubated or without antibodies then inoculated onto upper...
The NSABP Trial B-31 and NCCTG N9831 (B-31/N9831 trials, Romond et al. in N Engl J Med 353:1673–84, 2005. doi: 10.1056/NEJMoa052122 ; Perez Clin Oncol 32:3744–52, 2014. 10.1200/JCO.2014.55.5730 ) established the efficacy of adjuvant trastuzumab for patients with HER2-positive early stage breast cancer. We aimed to estimate overall survival (OS) relapse-free (RFS) non-metastatic cancer treated a clinical practice setting United States. Adult women initiating within 1 year surgery were...
Abstract Denileukin diftitox (DT) depletes regulatory T cells (Treg) that correlates with immune and clinical benefits in metastatic human melanoma improved outcomes a renal cancer vaccine trial. We tested effects of Treg depletion using DT phase 0/I trial II ovarian In our trial, we noted reductions blood prevalence concentration (median ~18% ~50%, respectively) 3-7 days after one intravenous infusion at 9 or 12 μg/kg, 6 7 evaluable patients breast, lung, cancers, melanoma, increased IFN-γ+...